399 related articles for article (PubMed ID: 20447562)
21. Safety, biodistribution, and dosimetry of 123I-IMPY: a novel amyloid plaque-imaging agent for the diagnosis of Alzheimer's disease.
Newberg AB; Wintering NA; Plössl K; Hochold J; Stabin MG; Watson M; Skovronsky D; Clark CM; Kung MP; Kung HF
J Nucl Med; 2006 May; 47(5):748-54. PubMed ID: 16644743
[TBL] [Abstract][Full Text] [Related]
22. Radiation dosimetry and pharmacokinetics of florbetapir (
Nakano M; Nakamura T; Takita Y; Uenaka K; Ando T; Senda M; Joshi AD; Lu M; Breault C; Pontecorvo MJ
Ann Nucl Med; 2019 Aug; 33(8):639-645. PubMed ID: 31140155
[No Abstract] [Full Text] [Related]
23. Using PET with 18F-AV-45 (florbetapir) to quantify brain amyloid load in a clinical environment.
Camus V; Payoux P; Barré L; Desgranges B; Voisin T; Tauber C; La Joie R; Tafani M; Hommet C; Chételat G; Mondon K; de La Sayette V; Cottier JP; Beaufils E; Ribeiro MJ; Gissot V; Vierron E; Vercouillie J; Vellas B; Eustache F; Guilloteau D
Eur J Nucl Med Mol Imaging; 2012 Apr; 39(4):621-31. PubMed ID: 22252372
[TBL] [Abstract][Full Text] [Related]
24. Perfusion-like template and standardized normalization-based brain image analysis using 18F-florbetapir (AV-45/Amyvid) PET.
Hsiao IT; Huang CC; Hsieh CJ; Wey SP; Kung MP; Yen TC; Lin KJ
Eur J Nucl Med Mol Imaging; 2013 Jun; 40(6):908-20. PubMed ID: 23412134
[TBL] [Abstract][Full Text] [Related]
25. Individualized quantification of brain β-amyloid burden: results of a proof of mechanism phase 0 florbetaben PET trial in patients with Alzheimer's disease and healthy controls.
Barthel H; Luthardt J; Becker G; Patt M; Hammerstein E; Hartwig K; Eggers B; Sattler B; Schildan A; Hesse S; Meyer PM; Wolf H; Zimmermann T; Reischl J; Rohde B; Gertz HJ; Reininger C; Sabri O
Eur J Nucl Med Mol Imaging; 2011 Sep; 38(9):1702-14. PubMed ID: 21547601
[TBL] [Abstract][Full Text] [Related]
26. GMP-compliant automated synthesis of [(18)F]AV-45 (Florbetapir F 18) for imaging beta-amyloid plaques in human brain.
Yao CH; Lin KJ; Weng CC; Hsiao IT; Ting YS; Yen TC; Jan TR; Skovronsky D; Kung MP; Wey SP
Appl Radiat Isot; 2010 Dec; 68(12):2293-7. PubMed ID: 20638295
[TBL] [Abstract][Full Text] [Related]
27. Initial human PET studies of metabotropic glutamate receptor type 1 ligand 11C-ITMM.
Toyohara J; Sakata M; Oda K; Ishii K; Ito K; Hiura M; Fujinaga M; Yamasaki T; Zhang MR; Ishiwata K
J Nucl Med; 2013 Aug; 54(8):1302-7. PubMed ID: 23804329
[TBL] [Abstract][Full Text] [Related]
28. Optimization of automated radiosynthesis of [18F]AV-45: a new PET imaging agent for Alzheimer's disease.
Liu Y; Zhu L; Plössl K; Choi SR; Qiao H; Sun X; Li S; Zha Z; Kung HF
Nucl Med Biol; 2010 Nov; 37(8):917-25. PubMed ID: 21055622
[TBL] [Abstract][Full Text] [Related]
29. Biological characters of [18F]O-FEt-PIB in a rat model of Alzheimer's disease using micro-PET imaging.
Zheng MQ; Yin DZ; Zhang L; Lei B; Cheng DF; Cai HC; Han YJ; Wu MX; Zhang H; Wang J
Acta Pharmacol Sin; 2008 May; 29(5):548-54. PubMed ID: 18430362
[TBL] [Abstract][Full Text] [Related]
30. Differential diagnosis in Alzheimer's disease and dementia with Lewy bodies via VMAT2 and amyloid imaging.
Villemagne VL; Okamura N; Pejoska S; Drago J; Mulligan RS; Chételat G; O'Keefe G; Jones G; Kung HF; Pontecorvo M; Masters CL; Skovronsky DM; Rowe CC
Neurodegener Dis; 2012; 10(1-4):161-5. PubMed ID: 22261520
[TBL] [Abstract][Full Text] [Related]
31. Brain and whole-body imaging in nonhuman primates with [11C]MeS-IMPY, a candidate radioligand for beta-amyloid plaques.
Seneca N; Cai L; Liow JS; Zoghbi SS; Gladding RL; Hong J; Pike VW; Innis RB
Nucl Med Biol; 2007 Aug; 34(6):681-9. PubMed ID: 17707808
[TBL] [Abstract][Full Text] [Related]
32. The use of the exploratory IND in the evaluation and development of 18F-PET radiopharmaceuticals for amyloid imaging in the brain: a review of one company's experience.
Carpenter AP; Pontecorvo MJ; Hefti FF; Skovronsky DM
Q J Nucl Med Mol Imaging; 2009 Aug; 53(4):387-93. PubMed ID: 19834448
[TBL] [Abstract][Full Text] [Related]
33. An exploratory efficacy study of the amyloid imaging agent [(18)F]flutemetamol in Japanese Subjects.
Senda M; Yamamoto Y; Sasaki M; Yamane T; Brooks DJ; Farrar G; McParland B; Heurling K
Ann Nucl Med; 2015 Jun; 29(5):391-9. PubMed ID: 25874747
[TBL] [Abstract][Full Text] [Related]
34. Preclinical Safety Evaluation and Human Dosimetry of [
Koole M; Lohith TG; Valentine JL; Bennacef I; Declercq R; Reynders T; Riffel K; Celen S; Serdons K; Bormans G; Ferry-Martin S; Laroque P; Walji A; Hostetler ED; Briscoe RJ; de Hoon J; Sur C; Van Laere K; Struyk A
Mol Imaging Biol; 2020 Feb; 22(1):173-180. PubMed ID: 31111397
[TBL] [Abstract][Full Text] [Related]
35. Whole-body biodistribution and radiation dosimetry of the human cannabinoid type-1 receptor ligand 18F-MK-9470 in healthy subjects.
Van Laere K; Koole M; Sanabria Bohorquez SM; Goffin K; Guenther I; Belanger MJ; Cote J; Rothenberg P; De Lepeleire I; Grachev ID; Hargreaves RJ; Bormans G; Burns HD
J Nucl Med; 2008 Mar; 49(3):439-45. PubMed ID: 18287275
[TBL] [Abstract][Full Text] [Related]
36. 18F-florbetapir PET in patients with frontotemporal dementia and Alzheimer disease.
Kobylecki C; Langheinrich T; Hinz R; Vardy ER; Brown G; Martino ME; Haense C; Richardson AM; Gerhard A; Anton-Rodriguez JM; Snowden JS; Neary D; Pontecorvo MJ; Herholz K
J Nucl Med; 2015 Mar; 56(3):386-91. PubMed ID: 25655625
[TBL] [Abstract][Full Text] [Related]
37. Dosimetry and efficacy of a tau PET tracer [
Ohnishi A; Akamatsu G; Ikari Y; Nishida H; Shimizu K; Matsumoto K; Aita K; Sasaki M; Yamamoto Y; Yamane T; Senda M
Ann Nucl Med; 2023 Feb; 37(2):108-120. PubMed ID: 36411357
[TBL] [Abstract][Full Text] [Related]
38. Optimal Target Region for Subject Classification on the Basis of Amyloid PET Images.
Carbonell F; Zijdenbos AP; Charil A; Grand'Maison M; Bedell BJ;
J Nucl Med; 2015 Sep; 56(9):1351-8. PubMed ID: 26135108
[TBL] [Abstract][Full Text] [Related]
39. Florbetapir F 18 for brain imaging of β-amyloid plaques.
Romano M; Buratti E
Drugs Today (Barc); 2013 Mar; 49(3):181-93. PubMed ID: 23527322
[TBL] [Abstract][Full Text] [Related]
40. Biodistribution and radiation dosimetry of the synthetic nonmetabolized amino acid analogue anti-18F-FACBC in humans.
Nye JA; Schuster DM; Yu W; Camp VM; Goodman MM; Votaw JR
J Nucl Med; 2007 Jun; 48(6):1017-20. PubMed ID: 17504867
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
